
host call jefbio team hc sector strategi et
rel strong bounc xbi ytd bunch gene therapi
investor feel good start year said think large-cap biotech ep
mix bag notabl season weakest print year given analysi
report surpris modest result typic little/no
guidanc bump lack high convict large-cap print
full report insid includ celg
season common theme caution co ep call
note enbrel specif guidanc part season note issu etc
celg gave specif guidanc guid qq
high convict print said buyer vs
factor play celg close spread april smid
particularli like amrn long side due strong demand
apr conf call go-forward biz alzheim
stock everyth tabl consid sharehold convict
matter call view management emphas season core
biz particularli headwind slower spinraza hemophilia
sale low margin hit cog think co work hard hit given
stock pressur extra magnifi scrutini thing co emphas
season question urgenc phase iib pivot psp tau data
summer scenario tecfidera ipr/ani settlement pot could biggest catalyst
apr look ok vs consensu particularli opex alway wild card
stock movement could pois potenti beat consensu
appear conserv high opex enbrel guid specif total revenu
similar dynam neulasta hold biosimilar per
possibl last call notabl management rule mega
despit bmy/celg deal fresh press
may dynam posit new ceo day board
ep call one might think would bad flip-sid
suggest similar qq declin last year bad quarter
inventori go high-end low-end true miss consensu
street qq bad last year think
conserv continu page detail analys other insid
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
summari chang
pleas see import disclosur inform page report
continu hiv biktarvi continu grow hcv script less bad
medicar price decreas impact overal lack convict would buy
dip given short-term bullish rest given uncertainti hit
quarter catalyst move higher recent pullback guidanc
fail nash studi
apr estimate focu call commerci launch recent approv
ultomiri soliri follow-on product fda approv dec updat
guidanc ultomiri price discount soliri pnh/ahu
patient convers conveni ultomiri soliri rapid could
potenti impact sale growth note soliri account alxn
total revenu histor provid conserv guidanc initi up
expect increment cours year estim
lower vs consensu total revenu vs con ep vs
con ep estim higher consensu vs
due lower opex in-lin revenu
apr focu call commerci launch palynziq fda approv
june potenti updat regulatori path manufactur progress
valrox gene therapi hemophilia potenti updat guidanc data
valrox expect potenti top-line data isth histor
provid well-project guidanc reiter cours year
estim line/wid vs consensu total revenu vs con
 lp vs con due higher opex
hold pt launch imvexxi strong rx number low
margin estim reflect revenu focus
continu rx growth importantli trajectori margin compani
work hard increas payer coverag number first true test
patient/pay mix better visibl health launch refer
model margin grow
buy pt earn focus commerci product
sale commentari pipelin progress commerci product expect
see steadi hetlioz sale due season vs follow
increment growth remaind stabil fanapt sale
pipelin updat mainli focus commentari relat on-going
lawsuit fda regard partial clinic hold tradipit judg case
grant stay fda day end april
pleas see import disclosur inform page report
tabl content
pleas see import disclosur inform page report
weekli script continu reach record high set amrn potenti
despit manag caution last earn call expect season
note script qtd track sale assum
inventori build vs con est jefferi histor vascepa
sale declin q/q declin script past coupl
year script reach all-tim high past week even though
sale sequenti higher third-parti data vs suggest im
script data could inaccur well manag recent confirm weekli
script quarter track fairli accur amrn intern talli
estim usa sale consid price increas enact dec
off-set slightli increas higher captur rate vs
deriv sale assum versu
quarter small inventori build
altern adjust captur rate histor norm estim
jefferi would yield usa sale closer rang would still
fall consensu estim
ex-u could also contribut sale benefit margin view
bigger pictur think guidanc appear conserv
suggest type trajectori modest quarterli growth
even though sale grew whop q/q
pleas see import disclosur inform page report
doctor consist provid posit feedback vascepa
anecdot doc inform us acceler prescript post
aha confer increas placebo arm miner oil deter
doc prescrib vascepa data one doctor increas prescript
use patient per month doctor prescrib sever
time month latter doctor formerli strong believ triglycerid tg
therapi unless patient exceed threshold envis
overal usag elev tg patient increas becom familiar
over-the-count supplement doc
feel comfort
recommend vascepa inform mani patient drug
fish oil show clear benefit large-scal random trial also reimburs
access vascepa issu doc particularli compar
pleas see import disclosur inform page report
pleas see import disclosur inform page report
lower ep vs con slightli lower revenu
higher expens higher tax rate product sale estim larg unchang
remain con primarili due lower revenu assumpt
aranesp neulasta enbrel sensipar
ep estim decreas lower revenu slightli
higher expens tax rate ep estimate slightli con within
guidanc toward midpoint full-year revenu
estim remain consensu primarili due lower sensipar
estim vs con delta
model chang decreas enbrel estim vs con
account higher de-stock rais aimvoig forecast
line consensu due stronger-than-expect script
data grew opex slightli higher estim increas
tax rate assumpt
per usual new guidanc provid ep appear conserv
us sinc suggest y/i declin total revenu vs y/i
ep vs y/i compar flattish growth rate estim
consensu time provid guidanc manag
incorpor follow high-level assumpt guidanc solid growth
newer product aimovig repatha biosimilar uncertainti around sensipar
gener competit potenti enbrel biosimilar competit net sell price
declin mid-singl digit vs among trend
believ wide ep guidanc rang larg driven
uncertainti around sensipar sale believ higher-end guidanc natur
assum sensipar gener entri lower-end assum assum entri earli
note teva gener launch last week short-liv
teva/amgn agre settl earli januari though launch could hurt small
portion upcom sensipar sale current estim ww sale vs
consensu q/q nonetheless expect sensipar sale
declin y/i driven part part switch increas market share parsabiv
temporari entri teva hurt sale
quarter sensipar gener enter market inclus addit
sensipar sale rais sale estim ww quarter could benefit
full-year ep estim depend time gener launch
includ start base con though teva
temporari entri inde neg impact sale start
 base con start base con
start base con
current gener version sensipar avail sale januari
waston/teva settl teva agre stop sell gener
sensipar paid undisclos amount januari
pleas see import disclosur inform page report
cipla su assert provis settlement agreement
trigger teva at-risk launch give cipla right market gener
version settlement agreement litig gener
well compani believ gener elect launch approv gener version
sensipar would at-risk prior conclus on-going litig
factor revenue/ep guidanc includ potenti biosimilar eros
neulasta discuss later report on-going enbrel biosimilar litig
sandoz enbrel close argument conclud believ court
decis could occur sometim could see upsid guidanc
litig stock could trade win scenario would
make current guidanc realist although would unclear whether sandoz
would launch risk addit manag note either outcom
could allow correspond parti challeng court decis via appeal
assumpt factor guidanc
includ impact potenti busi develop activ
sale percentag product sale look similar percentag
year-ago period histor repres lowest product sale quarter
year assum product sale repres full-year sale vs
consensu compar
enbrel sale percentag full-year sale look similar
percentag assum enbrel sale repres full-year sale vs
consensu line prior year
quarterli share perform price evolut enbrel stabl
next quarter
aranesp sale declin faster rate due long-act short-act
competit assum y/i declin vs con y/i
eu sale declin y/i driven increas competit long-act
biosimilar launch entrant expect assum
y/i declin eu sale vs con
revenu reflect non-recur natur
mileston payment receiv assum revenu vs con
opex flat y/i absolut basi model modest y/i declin
versu flattish y/i estim consensu
 expens increas pipelin advanc model flattish y/i growth versu
y/i increas consensu
cog flat slightli depend volum estim flattish y/i growth in-
line consensu
sg declin launch expens normal continu resourc
non-gaap tax rate incorpor tax rate earn
tax rate ex-u earn
repurchas activ look similar pace oper
previous repurchas share total
pleas see import disclosur inform page report
estim buyback share vs con estim repurchas
around share
neulasta biosimilar taken share gain past month
fulphila udenyca two biosimilar approv although
surpris see other enter market accord im feb
data fulphila garner market share month launch udenyca
taken share second month launch feb sale
fulphila m/m udenyca m/m compar
versu neulasta repres combin biosimilar/brand
notabl onpro sale feb total brand neulasta
im suggest sale may partial block
think take combin share year in-lin
consensu forecast neulasta sale
exhibit neulasta vs udenyca/fulphila sale time base monthli im sale
pleas see import disclosur inform page report
accord fulphila achiev share pre-fil syring market feb
estim pre-filled market repres share
consist im data
compani see increas weekli chargeback
salesforc select custom date
sep su assert fulphila infring two patent case
on-going trial date schedul yet
launch udenyca earli januari
unlik target launch respect particular market
segment rather focus broadli segment
compani see clear valu proposit hospit outpati segment
fact approv udenyca transit pass-through payment statu
effect april grant udenyca month transit pass-through statu
mean udenyca calcul list price wac
establish asp averag sale price udenyca reimburs
calcul neulasta asp comparison neulasta reimburs asp
anticip take quarter udenyca work way
ecosystem segment hospit clinic
argu onpro premium-pr product market cope
cost constraint increas cost due new therapi i/o believ
payor could find biosimilar like udenyca attract sinc price less
underli patient demand cgrp migrain drug look solid
aimovig trx track around q/q flattish believ could translat
usa sale vs con depend amount freesampl
provid patient quarter addit sale would suggest growth
q/q factor account adjust amount
paid prescript q/q think percentag
increas modestli quarter go forward free drug sampl convert
dollars/revenu
estim usa aimovig sale line consensu
slightli lower consensu due conservat estim
base sampl rate treat patient howev could
arriv aimovig sale base sampl rate
base sampl rate
assum higher assumpt vs histor plan
doubl coverag versu
current standard care consist repurpos therapi anticonvuls
antidepress decade-old drug patient discontinu drug
within year therapi
consist doc feedback discontinu rate aimovig low
clinic set case manag believ patient
pleas see import disclosur inform page report
fail prevent therapi fail triptan howev none payor
discuss thu far suggest aimovig patient need fail botox
importantli believ first-to-market distinct advantag
compani estim larg bolu patient come aimovig quickli
consist current script trend
importantli launch teva ajovi lli emgal still track
fraction aimovig script
ajovi approv sep subsequ launch week end
emgal approv sep subsequ launch week
similar aimovig ajovi emgal price per month
commerci insur patient teva offer littl co-pay ajovi
provid free sampl program emgal
teva report ajovi sale report emgal sale
teva anticip ajovi sale reach
teva ajovi script recent nrx week launch
vs nrx aimovig period
emgal script recent nrx week
launch vs nrx aimovig nrx ajovi
period
pleas see import disclosur inform page report
exhibit aimovig script project migrain
pleas see import disclosur inform page report
script track usa
exhibit repatha vs regn/sni praluent script project left red line repres histor im data
pleas see import disclosur inform page report
pleas see import disclosur inform page report
exhibit monthli sale comparison versu zarxio granix
pleas see import disclosur inform page report
exhibit guidanc versu consensu jefferi estim
pleas see import disclosur inform page report
pleas see import disclosur inform page report
manag emphas investor expect season core
busi particularli due strong print headwind quarter includ
slower spinraza growth q/q hemophilia sale low margin hit cog
whether one-tim cost associ aducanumab program shut
said think compani would work dilig hit given stock
pressur compani magnifi scrutini key question
urgenc even nite acquisit phase iib pivot psp data
summer offici guidanc scenario tecfidera ipr includ
potenti settlement could biggest catalyst
ep estim consensu driven
higher revenu lesser expens delta impact ep
believ remain differ ep could attribut
consensu possibl assum expens collabor profit loss
share agreement samsung agreement includ share profit
loss relat biosimilar partnership samsung meanwhil revenu
estim slightli consensu due slightli higher ms
ww revenu estim con toward
midpoint guidanc lower revenu assumpt driven primarili
lower spinraza sale vs con delta tysabri sale
delta revenu delta off-set higher revenu
delta ep estim consensu toward lower end
guidanc due assumpt lower revenu higher expens
ms channel build y/i
manag cite extern factor beyond control
tecfidera benefit channel inventori y/i
avonex/plegridi benefit channel inventori y/i
saw increas discount expect season affect
compani expect potenti inventori drawdown note vast
major burn quarter
expect rate chang full-year ms sale exclud ocrevu
similar versu mostli off-set growth ocrevu royalti
expect spinraza grow mid-to-high teen growth
us ou ou grow slower pace
howev spinraza revenu stabl flat q/q due season
expect see quarterli spinraza sale growth
expect double-digit growth biosimilar primarili driven recent imraldi launch
pleas see import disclosur inform page report
expect slight declin revenu due launch rituxan
biosimilar
expect modest increas revenu revenu heavili load due
effect time sale remain inventori associ
bioverativ spin-off carri low gross margin
expect gross margin compress due sale remain
bioverativ inventori impact virtual record
gross margin around
 expens includ expens relat skyhawk partnership
opex per quarter prepar launch aducanumab
could longer case could see rais ep guidanc
follow discontinu aducanumab phase studi
net expens lower vs due higher interest incom
attribut larger cash balanc higher interest rate
us corpor tax reform benefit tax rate bp
expect record after-tax loss impli
ep impact due sale large-scal biolog manufactur site denmark
fujifilm believ sale repres adjust
march author program repurchas stock
repurchas intend retir believ announc suggest
compani prefer buyback shorter-term
spinraza sale grow albeit slower pace
expect spinraza grow mid-to-high teen growth
us ou although ou grow slower pace howev spinraza
revenu stabl flat q/q due season expect see
spinraza sale grow quarter
estim spinraza ww sale us/ ex-u
consensu flat q/q
estim spinraza ww sale us/ ex-u slightli
consensu y/i
investor awar competit headlin risk oral ptct/roch
data nv gene therapi confer may recent met
roch manag confirm plan file broad label year oral drug
come
nv compani prepar us launch sma gene therapi zolgensma
type sma may pdufa date nv plan present new data
intrathec formul type patient strong
key catalyst phase iv infus pre-symptomat type patient
sprint long-term dose-escal phase iv infus data type
patient start phase iv infus data type patient strive japan
eu approv type expect respect nv
hint multi-million dollar price tag zolgensma cite recent icer draft report
pleas see import disclosur inform page report
affirm zolgensma valu classifi ultra-rar diseas
threshold vs spinraza year annual
upcom type data posit strong nv hope parlay result
current bla file potenti receiv broader label note type
result predict type patient discuss fda
construct thu far otherwis base case scenario file type later
interestingli nv manag recent comment understand
result unfold given strong open-label studi type
strong studi open-label phase evalu three dose zolgensma
patient mid dose cohort fulli recruit recal type
data start basi current bla file show patient aliv
without requir perman ventil month receiv
propos therapeut dose could sit unassist second
also nv also work oral sma drug branaplam
rna splice modul current open-label phase ii studi data
type patient expect
roche/ptct partner plan file oral risdiplam type base
recent fda feedback part firefish type sunfish type could
suffici file present interim part data oct
compani could present part pivot data firefish/sunfish updat
data abstract also evalu anoth type sma studi jewelfish
treatment-experienc patient data perhap curesma
pleas see import disclosur inform page report
pleas see import disclosur inform page report
thought tecfidera sale
tecfidera script q/q impli script revenu usa includ
inventori drawdown assumpt vs consensu model also account
price increas enact jan off-set higher assumpt bp
vs account season recent submit nda
vumer confer better gi safeti profil tecfidera
compani plan report addit head-to-head data recent confer
ceo michel vounatso note compani strategi switch patient
tecfidera vumer instead expand overal ms market
tecfidera inventori trend follow
inventori saw draw q/q
inventori level rel constant q/q build drawdown
inventori level drawdown
inventori level rel constant q/q
inventori level increas q/q
inventori level decreas q/q
inventori level decreas q/q
inventori level stabl q/q
inventori level increas q/q
assum inventori drawdown around q/q
bear argu uncertainti tecfidera given ipr recent
institut good proport decis rule innov ipr end
dcf suggest downsid support assum tecfidera
goe away start ipr favor think dcf worth back
fact uber-bear would argu ep get hit big
current tecfidera goe away tecfidera may contribut ebit
strip high-margin rev tax also goe due tecfidera irish domicil
ep goe toward price-to-earnings generalist may argu use
price-to-earnings forward ep celg went theoret use price-to-earnings
pleas see import disclosur inform page report
downward ep ex-tecfidera patent loss post though note dcf may
ocrevu multipl sclerosi market
ocrevu im script unreli monitor whether tecfidera script
affect launch ocrevu gener ww sale
mostli us sale repres fastest launch roch histori
ocrevu approv rm ppm countri patient
treat
roch attract treatment-na patient switch earlier line
therapi vs switch later line previous
ocrevu share switch new start rm therapi
share remain market share
roch confirm ppm sale still increas even compani treat
initi bolu patient time ocrevu launch
pleas see import disclosur inform page report
pleas see import disclosur inform page report
exhibit guidanc versu consensu jefferi estim
pleas see import disclosur inform page report
pleas see import disclosur inform page report
rais ep estim vs con reduc
expens line con lower revenu estim slightli
in-lin con account season
donut hole impact typic reduc total product
sale estim better-align manag guidanc sale
repres full-year sale line con addit
total product sale estim broadli line sale consist
manag guidanc
rais ep estim vs con guidanc
assumpt higher revenu better expens manag
revis product sale estim vs previous lower
consensu toward midpoint guidanc gener
consensu pomalyst abraxan otezla revenu
estim product in-lin manag individu product guidanc
see upsid revlimid sale due potenti us/eu label expans
combo inhl fda approv expect rvd combo r/r mm
ex-u approv march newly-diagnos multipl myeloma ndmm
roll submiss complet mid-march revlimid estim
guidanc consensu estim
thesi continu iss recent favor bmy/celg deal
celg stock recent climb posit recommend iss support
bmy/celg merger develop consist thesi expect
remain spread ex-cvr write narrow april
vote et believ recommend significantli increas chanc
deal close sinc much sharehold base inclin side iss
view
iss believ propos merger offer strateg rational valuat appear
reason given competit pressur synergi within market product
includ oncolog would drive cost save synergi deal would enabl
diversifi revenu stream away opdivo factual repres
revenu goe patent face increas pressur
keytruda roch tecentriq deal bolster pipelin would increas
number late-stag pipelin drug ozanimod fedratinib
luspatercept valuat appear reason revlimid ip situat difficult
predict recent develop appear favor scenario assum due
recent posit ipr develop mani datapoint suggest like acquir
 commentari ceo multipl big pharma except
pleas see import disclosur inform page report
otezla script q/q track in-lin consensu
im data show otezla script grow q/q suggest usa sale
line consensu estim modest growth
pleasant surpris sinc celg caution expect typic demand soften
believ could increas rang around q/q
compani caution typic demand
sale ww us/ ex-u consensu driven
new-to-brand market share
celg believ otezla market opportun lie pre-biologic/post-top set
otezla patient come pre-biolog set otezla primarili serv
patient come topic otezla market share momentum appear
unaffect newer biolog drug launch recent
forecast world-wide otezla revenu vs guidanc
consensu also line
believ im track usa revenu would mean
ex-u revenu would surpass year reach manag
guidanc rang
believ ex-u otezla sale achiev sale
suggest annual run rate alreadi model us sale
ex-u sale
pleas see import disclosur inform page report
exhibit otezla sale project base im script
pleas see import disclosur inform page report
exhibit guidanc versu consensu jefferi estim
pleas see import disclosur inform page report
pleas see import disclosur inform page report
thought
acknowledg stock could take time regain momentum post
nash data recent management chang see stock move
low level time sinc stock alreadi favor sentiment low
stock low end trade rang trade price-to-earnings
investor sharehold base stock alreadi understand chang
long-term view anyway earn call new ceo daniel day
like convey thought around growth/dur hiv potenti filgotinib
oncolog potenti instil investor confid could also mention
strategi vision put balanc sheet work next month
take much get investor excit sinc expect low alreadi
given uncertainti number year management guidanc impli flattish
y/i revenu growth stock move announc deal next
month hit hiv number cleanli year hcv becom smaller impact
overal busi thesi tie hiv growth
model chang thought
reduc total revenu estim consensu
due
slightli softer-than-expect us hcv revenu script declin
reduc hcv sale slightli vs con
consensu us assum hcv sale declin declin
y/i midpoint manag guidanc
mean sequenti declin like factor manag guidanc
assumpt hiv inventori quarter may fluctuat higher-
end lower-end rang potenti drive addit hiv sale declin
rang alreadi consid q/q declin
us hiv sale due season inventori purchas inventori build favor
payor mix lower benefit combin q/q
total product estim impli q/q declin vs
previous line guidanc con
ep estim reduc remain con
primarili due lower expens mostli due cog off-set lower
revenu slightli lesser repurchas activ assumpt compar
consensu estim lower revenu hurt ep cent
lesser expens benefit ep cent
consensu model gross margin vs guidanc
estim point gross margin improv benefit ep
investor voic concern potenti miss total product sale
consensu would impli q/q sale declin versu guidanc
investor believ consensu number look larg achiev
take stanc double-digit percentag q/q declin larg attribut
overconservat manag
pleas see import disclosur inform page report
believ key swing factor quarter could amount inventori drawdown
note season inventori purchas inventori build favor
payor mix lower benefit sale combin q/q
model q/q product sale declin q/q look similar
guidanc q/q oppos consensu q/q
sale declin q/q equival swing around
refer usa hiv sale q/q
model usa hiv sale mathemat account
impact assum addit inventori
fluctuat q/q organ growth
howev hiv franchis fundament grow busi driven biktarvy/
genvoya guidanc assum y/i sale increas hiv
biktarvi script look solid grow q/q origin expect
suggest potenti beat quarter
moreov ranexa letairi sale could partial off-set expect q/q sale
declin margin impact histor letairi ranexa gener
combin quarter consensu model total sale
howev awar gener launch version quarter
brand product could repres revenu upsid
least
ranexa expect face gener competit start
letairi expect face gener competit start patent
ambristentan activ ingredi letairi expir juli
fda approv four letairi gener march teva sun pharma
zydu gener yet launch
bottom line view inventori revers one-tim event could off-set
expens reduct and/or buyback even though consensu estim total sale
could could easili make result ep differ
expens reduct and/or buyback instanc high chanc manag
could lower full-year sg guidanc data read neg
sinc current guidanc assum increas sg prepar
commerci launch nash invest inflamm expand geograph
hcv script q/q vs franchis
repres small portion total product sale
even though hcv script
consensu assum y/i declin hcv sale midpoint
manag guidanc suggest sequenti
declin could well factor guidanc im model suggest script
could track havoni epclusa/vosevi/sovaldi bigger
pictur revenu growth hiv franchis off-set market dynam
hcv franchis view
estim hcv sale ww q/q consensu
flattish growth
pleas see import disclosur inform page report
estim hcv sale ww y/i line consensu
within guidanc
hcv sale ww includ us ou
forecast usa sale q/q declin account script
volum declin well step-down price hcv drug sold medicar
trend bake manag guidanc
hcv data point thought
mavyret sale exceed vs
respect hold global hcv market share
expect global hcv sale includ ex-u sale
guidanc assum roughli flat perform could hint
stabil market
manag expect hcv revenu fall
exhibit harvoni sovaldi epclusa vosevi script project
pleas see import disclosur inform page report
exhibit consensu estim annual hcv sale world-wide
pleas see import disclosur inform page report
pleas see import disclosur inform page report
biktarvi script continu grow week think consensu estim
achiev vs even though im note script partial
block biktarvi surpass initi script genvoya strongest
hiv launch histori look close weekli growth continu trend upward
suggest biktarvi track reach consensu estim
biktarvi us prescript deriv switch came
dtg anoth genvoya
importantli would stress biktarvi strong start thesi hing
total hiv sale franchis shorter-term believ
hiv sale growth driven genvoya/biktarvi revenu
longer term manag remain confid biktarvi sale continu outpac
manag expect hiv busi grow double-digit
percentag increas y/i vs jefferi
addit hiv growth driven sole us expect growth
eu year driven launch gener hiv product account adjust
relat revenu clawback reserv
howev expect eu hiv busi return growth period
biktarvi becom broadli reimburs region
rais price hiv product includ biktarvi
exhibit compar launch trajectori biktarvi vs hiv drug launch
note gsk recent file two-drug regimen fda compani
expect receiv fda approv also compani recent present posit
data long-act inject two-drug regimen cab rpv flair atla studi
gsk plan file nda cab rpv potenti approv
expect
pleas see import disclosur inform page report
gsk note dynam hiv busi vari geographi
dtg triumeq busi essenti flat past
month gsk saw switch product
go forward gsk expect deriv hiv growth juluca
ex-u gsk expect gener hiv growth across broad dtg portfolio
gsk expect hiv sale grow slower rate busi matur
competit heighten
pleas see import disclosur inform page report
pleas see import disclosur inform page report
exhibit guidanc versu consensu jefferi estim
pleas see import disclosur inform page report
pleas see import disclosur inform page report
consensu model total cf revenu q/q
declin due neg impact inventori drawdown q/q
higher adjust saw inventori build impli organ cf sale
howev model modest q/q declin cf monthli model
orkambi symdeko suggest total cf revenu could closer estim
 q/q declin even consid drawdown higher
assumpt vs tradit sinc expect see continu ex-u
growth driven symdeko second quarter launch eu germani
orkambi launch canada eu patient age new market opportun
refer cf sale declin q/q due similar drawdown/
consensu model total cf revenu alreadi
guidanc versu sale believ
good chanc rais full-year revenu guidanc sinc annual organ
revenu exclud inventori build impli sale
alreadi lower-end guidanc bottom line believ sale growth
come patient exist label necessarili new launch new
exhibit guidanc versu consensu jefferi estim
believ abl deriv y/i revenu growth addit
ex-u sale orkambi symdeko drug garner market share
canada australia european region and/or launch addit countri
instanc orkambi approv dec children age canada
eu well kalydeco jan children age canada also note franc
uk would definit repres upsid surpris sinc consensu exclud
revenu two countri symdeko sale growth due new entri
age popul think approv later plu continu penetr
orkambi-experienc patient meanwhil us revenu okambi kalydeco
pleas see import disclosur inform page report
exhibit project cf revenu product
pleas see import disclosur inform page report
pleas see import disclosur inform page report
pleas see import disclosur inform page report
pleas see import disclosur inform page report
factset jefferi
focu call commerci launch recent approv ultomiri soliri
follow-on product fda approv dec updat guidanc
ultomiri price discount soliri pnh/ahu patient
convers conveni ultomiri soliri rapid could potenti
impact sale growth note soliri account alxn total revenu
histor provid conserv guidanc initi up expect
increment cours year estim lower vs
consensu total revenu vs con ep vs con
ep estim higher consensu vs due lower
opex in-lin revenu
pleas see import disclosur inform page report
factset jefferi
focu call commerci launch palynziq fda approv june
potenti updat regulatori path manufactur progress valrox gene
therapi hemophilia potenti updat guidanc
data valrox expect potenti top-line data isth
histor provid well-project guidanc reiter cours
year estim line/wid vs consensu total revenu
vs con lp vs con due higher opex
pleas see import disclosur inform page report
pleas see import disclosur inform page report
pleas see import disclosur inform page report
pleas see import disclosur inform page report
estim valuat
pleas see import disclosur inform page report
